CANCERS BRONCHIQUES A PETITES CELLULES
ESSAIS TESTANT DIFFERENTS DOSAGES POUR UNE MEME COMBINAISON DE MEDICAMENTS

Précédent Retour au menu principal  Suivant


Référence

chimiothérapie avec dosage (mg/m²)

stade

nb pts

RO

p

SM

p

Cohen,

1977 (1)

  CCNU-MTX- CPA

tous

 

 

 

 

ND

 

 

 

ND

1.   100    15     1000

23

96%

 

2.     50    10       500

9

45%

 

Figueredo,

1985 (2)

  ADR-VCR-CPA

tous

 

 

 

 

NS

 

 

 

NS

1. 60      1     1500-2000

52

71%

 

2. 50      1     1000

51

61%

 

O’Donnell,

1985 (3)

   CPA- VCR- meCCNU

tous

 

 

 

 

NS

 

 

 

NS

1. 2000     2           100

14

43%

43s

2.   750     2             75

14

72%

36s

Wolf,

1986 (4)

 

     VP16    J1-3

tous

! pré-traités

 

 

 

 

 

 

NS

 

 

 

 

NS

1. 100

26

4%

12,6s

2. 200

27

7%

20,0s

3. 300

26

4%

22,5s

Johnson,

1987 (5)

     CPA-ADR-VCR

ME

 

 

 

 

S

 

 

 

NS

1.  1200   70     1

101

64%

29,3s

2.  1000    40    1

146

53%

34,7s

Arriagada,

1993 (6)

 CPA-CDDP-ADR-VP16

 ( !1ère cure seulement)

ML

 

(CR)

 

 

 

NS

à 2 ans

 

 

 

S

1. 1200   100      40    225

51

67%

43%

2.   900    80       40    225

48

54%

26%

Ihde,

1994 (7)

     CDDP – VP16

ME

 

 

 

 

NS

 

 

NS

1.   135          400

44

86%

11m

2.     80          240

46

83%

10m

Pujol,

1997 (8)

     CPA-Epir-VP16-CDDP

ME

 

 

 

 

NS

 

 

 

S

1.  1800  60    330     120

65

87%

8,9m

2.  1200  40    225     100

60

74%

11m

Ardizzoni,

2005 (9)

CDDP – VP16 + G-CSF

tous

 

 

 

 

 

1. 25x2 – 60x3

28

39%

31 s

2. 40x2 – 100x3

67

69%

41 s

Leyvraz,

2008 (10) A

1. Intensif : 2 cycles paclitaxel + épirubicine (collecte PBPC) puis 3 cycles Ifo (2,5 x 4) + Carbo (AUC 5x4) + VP16 (300 x 4)

tous

69

78 %

NS

17,3 m

NS

2. Standard : 6 cycles Ifo (5) + Carbo (300) + VP16 (180 x 3)

71

68 %

14,4 m



Références

(1) Cohen MH, Creaven PJ, Fossieck BEJ, Broder LE, Selawry OS, Johnston AV et al. Intensive chemotherapy of small cell bronchogenic carcinoma. Cancer Treat Rep 1977; 61(3):349-354.

(2) Figueredo AT, Hryniuk WM, Strautmanis I, Frank G, Rendell S. Co-trimoxazole prophylaxis during high-dose chemotherapy of small-cell lung cancer. J Clin Oncol 1985; 3(1):54-64.

(3) O'Donnell MR, Ruckdeschel JC, Baxter D, McKneally MF, Caradonna R, Horton J. Intensive induction chemotherapy for small cell anaplastic carcinoma of the lung. Cancer Treat Rep 1985; 69(6):571-575.

(4) Wolff SN, Birch R, Sarma P, Greco FA. Randomized dose-response evaluation of etoposide in small cell carcinoma of the lung: a Southeastern Cancer Study Group Trial. Cancer Treat Rep 1986; 70(5):583-587.

(5) Johnson DH, Einhorn LH, Birch R, Vollmer R, Perez C, Krauss S et al. A randomized comparison of high-dose versus conventional-dose cyclophosphamide, doxorubicin, and vincristine for extensive-stage small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group. J Clin Oncol 1987; 5(11):1731-1738.

(6) Arriagada R, Le Chevalier T, Pignon JP, Riviere A, Monnet I, Chomy P et al. Initial chemotherapeutic doses and survival in patients with limited small-cell lung cancer. N Engl J Med 1993; 329(25):1848-1852.

(7) Ihde DC, Mulshine JL, Kramer BS, Steinberg SM, Linnoila RI, Gazdar AF et al. Prospective randomized comparison of high-dose and standard-dose etoposide and cisplatin chemotherapy in patients with extensive-stage small-cell lung cancer. J Clin Oncol 1994; 12(10):2022-2034.

(8) Pujol JL, Douillard JY, Riviere A, Quoix E, Lagrange JL, Berthaud P et al. Dose-intensity of a four-drug chemotherapy regimen with or without recombinant human granulocyte-macrophage colony-stimulating factor in extensive-stage small-cell lung cancer: a multicenter randomized phase III study. J Clin Oncol 1997; 15(5):2082-2089.

(9) Ardizzoni A, Favaretto A, Boni L, Baldini E, Castiglioni F, Antonelli P et al. Platinum-etoposide chemotherapy in elderly patients with small-cell lung cancer: results of a randomized multicenter phase II study assessing attenuated-dose or full-dose with lenograstim prophylaxis--a Forza Operativa Nazionale Italiana Carcinoma Polmonare and Gruppo Studio Tumori Polmonari Veneto (FONICAP-GSTPV) study. J Clin Oncol 2005; 23(3):569-575.

(10) Leyvraz S, Pampallona S, Martinelli G, Ploner F, Perey L, Aversa S, et al. A threefold dose intensity treatment with ifosfamide, carboplatin, and etoposide for patients with small cell lung cancer: a randomized trial. J Natl Cancer Inst 2008 Apr 16;100(8):533-41.



Retour au début de la page